Two Sigma Advisers LP Sells 330,600 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Two Sigma Advisers LP lowered its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 55.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 261,400 shares of the company's stock after selling 330,600 shares during the period. Two Sigma Advisers LP owned approximately 0.28% of Scholar Rock worth $11,298,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of SRRK. FMR LLC increased its position in shares of Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Scholar Rock by 7.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock valued at $401,231,000 after purchasing an additional 629,315 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares during the last quarter. Marshall Wace LLP increased its position in shares of Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after purchasing an additional 2,732,546 shares during the last quarter. Finally, Bellevue Group AG increased its position in shares of Scholar Rock by 16.2% during the 4th quarter. Bellevue Group AG now owns 2,510,690 shares of the company's stock valued at $108,512,000 after purchasing an additional 349,487 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $30.46 on Friday. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average price is $30.85 and its 200-day moving average price is $35.93. The firm has a market cap of $2.89 billion, a P/E ratio of -12.96 and a beta of 0.37. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the previous year, the company posted ($0.59) earnings per share. On average, equities research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Scholar Rock

In other news, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares in the company, valued at approximately $3,966,108.90. The trade was a 56.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Katie Peng sold 1,006 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now owns 30,319 shares in the company, valued at $1,043,579.98. The trade was a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,798 shares of company stock worth $5,482,238 over the last quarter. Insiders own 13.30% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.